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Abstract
Here we describe a strategy to model blood vessel development using a well-defined iPSC-derived 
endothelial cell type (iPSC-EC) cultured within engineered platforms that mimic the 3D 
microenvironment. The iPSC-ECs used here were first characterized by expression of endothelial 
markers and functional properties that included VEGF responsiveness, TNF-α-induced 
upregulation of cell adhesion molecules (MCAM/CD146; ICAM1/CD54), thrombin-dependent 
barrier function, shear stress-induced alignment, and 2D and 3D capillary-like network formation 
in Matrigel. The iPSC-ECs also formed 3D vascular networks in a variety of engineering contexts, 
yielded perfusable, interconnected lumen when co-cultured with primary human fibroblasts, and 
aligned with flow in microfluidics devices. iPSC-EC function during tubule network formation, 
barrier formation, and sprouting was consistent with that of primary ECs, and the results suggest a 
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VEGF-independent mechanism for sprouting, which is relevant to therapeutic anti-angiogenesis 
strategies. Our combined results demonstrate the feasibility of using a well-defined, stable source 
of iPSC-ECs to model blood vessel formation within a variety of contexts using standard in vitro 
formats.
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INTRODUCTION
The lack of a functional vasculature in healing or transplanted tissues has motivated efforts 
to deconstruct the critical factors that stimulate blood vessel maintenance and growth[1, 2]. 
Hydrogels with defined extracellular matrix (ECM) properties[3–5] and microfluidics 
approaches for controlling soluble gradients, flow, and surface shear[6, 7] have been used to 
model vasculature in 3-dimensional (3D) microenvironments[8–10]. However, the 
complexity of blood vessel specification and heterogeneity of primary human endothelial 
cells[11] limits the robustness of engineered vascular models. Robust models of vasculature 
are likely required for emerging tissue modeling applications that rely on standardization 
and quantitative readouts to enable toxicity and drug screening[12–15].
Human pluripotent stem cells have received increasing attention for tissue modeling 
applications, as they provide a well-defined source of tissue-specific cell types[16–18]. 
Induced pluripotent stem cells (iPSC) are a particularly promising cell source for modeling 
tissue development and pathologies associated with specific genetic defects, since patient-
derived tissues can be generated using both disease-relevant cell lines and control cell 
lines[19–22]. Multiple strategies for human endothelial cell (EC) differentiation have been 
reported for both embryonic stem cells and induced pluripotent stem cells[23–28]. Thus, 
human iPSC-derived endothelial cells (iPSC-ECs) represent a potentially valuable tool for 
the development of robust and reproducible vascular tissues for disease modeling and 
screening applications[12–15].
Here we demonstrate that human iPSC-ECs reproduce functional properties reported for 
primary ECs using multiple engineered in vitro environments. The iPSC-ECs were 
characterized by expression of characteristic EC markers, including >90% PECAM1+/ENG+ 
(CD31+/CD105+), observed across 3 separate production lots and 6 passages in culture. The 
iPSC-ECs were characterized by VEGF responsiveness in multiple contexts, thrombin-
dependent barrier function, acetylated LDL uptake, and unregulated expression of 
characteristic blood vessel cell adhesion molecules MCAM (CD146) and ICAM-1 (CD54) 
in response to TNF-α. Further, iPSC-ECs assembled into capillary-like networks on 2D 
substrates and within 3D Matrigel culture, aligned with the direction of fluid flow, and 
formed perfusable lumen within microfluidics devices. A quantitative sprouting assay with 
iPSC-ECs was developed and demonstrated dependence on vascular endothelial growth 
factor (VEGF) and fibroblast growth factor-2 (FGF-2) signaling, as well as microtubule 
stability, in agreement with previous studies. The sprouting assay identified context-specific 
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pharmacological inhibition with implications for screening and development of anti-
angiogenic drugs. Finally, results showed that synergistic signaling through FGF-2 and 
VEGF enhanced iPSC-EC sprouting, although VEGF/VEGF receptor 2 (VEGFR2) 
signaling was not necessary to induce sprout formation. Taken together, our results 
demonstrate the suitability of a defined human iPSC-EC line for investigating vascular 
biology in multiple distinct experimental contexts.
RESULTS
iPSC-ECs robustly express endothelial markers and respond to VEGF signaling
iPSC-ECs exhibited function and marker expression consistent with previous studies of 
primary endothelial cells. iPSC-ECs actively internalized acetylated LDL as a substrate 
(Suppl. Fig. 1A)[29], stained positive for UEA-1 (Fig. 3D)[30], and expressed von 
Willebrand factor (vWF, Suppl. Fig. 1C–D), CD31 (PECAM1, Fig. 1A–C), endoglin (ENG/
CD105; Fig. 1A, 1C), VE-cadherin (CD144, Fig. 1B), and VEGFR2/KDR (Fig. 1D) with 
high purity[25]. Further, iPSC-ECs proliferated in response to VEGF-A (hereafter referred 
to as VEGF) in a dose-dependent fashion (Fig. 1E). The proliferative response for iPSC-ECs 
was reduced by the VEGFR2 inhibitor SU1498 [31] (Fig. 1F), which is consistent with a 
role of VEGF/VEGFR2 signaling for promoting normal endothelial cell function[32, 33]. 
Greater than 90% of the iPSC-EC population was CD31+/CD105+ from three independent 
production runs and over six passages in culture (Fig. 1C). Thus, the iPSC-ECs stably 
expressed purity markers during routine culture and exhibiting functional characteristics 
consistent with primary ECs.
iPSC-ECs exhibit barrier function, exhibit wound healing behavior, and respond to 
inflammatory stimuli
Endothelial cells change their barrier properties during wound healing and inflammation[34] 
and differentially express the adhesion molecules intercellular adhesion molecule (ICAM) 
and melanoma cell adhesion molecule (MCAM) to recruit circulating immune and 
progenitor cells[35]. We thus characterized iPSC-EC barrier function in response to a wound 
healing stimulus and marker expression upon cytokine challenge. ZO-1 expression at the 
cell borders for iPSC-ECs (Fig. 2A) provided evidence of tight junction formation[36, 37]. 
We further investigated the ability of iPSC-ECs to form a barrier using an impedance-based 
platform to assess barrier function (see Methods)[34]. Impedance measurements 
demonstrated that iPSC-ECs formed functional barriers that were disrupted by thrombin 
treatment (Fig. 2B) and were recoverable at lower continuous thrombin doses (Fig. 2B; Blue 
and Green traces). Thus, iPSC-ECs exhibited reversible changes in barrier function 
consistent with previous studies of EC monolayers treated with edemagenic agents 
(including thrombin) at low concentrations[38, 39]. We further investigated the capacity for 
iPSC-ECs to express cell adhesion molecules (CAMs) in response to TNF-α stimulation 
(Fig. 2C–F), thus recapitulating EC properties necessary for cell recruitment during wound 
healing and inflammation[35]. Flow cytometry analysis demonstrated that TNF-α treatment 
induced upregulation of ICAM-1 (CD54; Fig. 2C–D) and MCAM (CD146; Fig. 2E–F), 
which are expressed by ECs to promote attachment of immune and progenitor cells to blood 
vessels[35]. These results indicate that iPSC-ECs functionally respond to stimuli required 
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for wound healing, and suggest that iPSC-ECs are a well-defined cell source for 
investigating blood vessel properties in vitro and understanding the transport of solutes or 
cells across blood vessel barriers[40].
iPSC-ECs align in response to shear stress and form capillary-like networks with 
perfusable lumen
A hallmark for endothelial cell function is the capacity to form capillary-like networks in 2D 
and 3D contexts[3–5, 23, 41–46]. Here, iPSC-ECs organized into cord-like networks on 
Matrigel-coated tissue culture polystyrene (TCP; Fig. 3A) or on thick Matrigel slabs (Fig. 
3C)[43, 44], with similar results observed for HUVECs (Fig. 3B; Matrigel-coated TCP). 
iPSC-ECs also formed 3D capillary-like networks when encapsulated in Matrigel (Fig. 3F). 
iPSC-ECs (Fig. 4D,F) and HUVECs (Fig. 4E) appeared to elongate towards the central axis 
of flow, but iPSC-ECs remained rounded (Fig. 4C) during static culture in a perfusable 
bioreactor[47], consistent with a possible role for shear stress in directing cytoskeletal 
organization[48]. To confirm the capacity for iPSC-ECs to align in response to shear stress, 
we used monolayer culture within a microfluidics device to quantitatively control chamber 
geometry and flow rate (Fig. 3E). An applied shear stress of 20 dyne/cm2 induced iPSC-ECs 
to elongate in the direction of 2D flow after 72hr (Fig. 4A,B), which is consistent with the 
behavior of primary endothelial cells as previously measured[48]. Finally, iPSC-ECs seeded 
in fibrin gels within a microfluidics device and co-cultured with normal human lung 
fibroblasts assembled into three dimensional, inter-connected capillary networks and formed 
cord-like structures containing visibly hollow lumens (Fig. 5A). The presence of 
interconnected vascular lumen for iPSC-ECs in fibrin gels was confirmed using 
epifluorescence microscopy to document the transport of 4 µm diameter beads through the 
capillary network (Fig. 5B, Suppl. Movie 1).
VEGF/VEGFR2 signaling influences iPSC-EC sprouting
Endothelial cell sprouting comprises the initial stage of angiogenesis, and assays for EC 
sprouting[49–52] represent valuable tools for the screening and development of 
angiogenesis regulators[53]. We developed and characterized an in vitro sprouting assay 
(Fig. 6A) to examine iPSC-EC behavior in response to stimulation by VEGF or inhibition by 
a library of pharmacological inhibitors (Fig. 6B). iPSC-ECs exhibited sprouting (Fig. 7C), 
migration (Fig. 8C), and invasion (Suppl. Fig 2C) that was dependent on the concentration 
of a microtubule polymerization inhibitor (nocodazole), which is consistent with a role of 
microtubules for regulating endothelial cell function in different contexts[54]. Importantly, 
sprouting behavior was dependent on the concentration of VEGF (Fig. 7A), consistent with 
VEGF-dependent sprouting of primary endothelial cells[50, 55]. Inhibition studies in 
VEGF-containing medium demonstrated that sprouting was abolished in the presence of a 
VEGFR2 inhibitor (SU1498), a tyrosine kinase inhibitor (Sunitinib) (Fig. 6E), and a FGFR/
VEGFR2 inhibitor (SU5402) (Fig. 7B), confirming that VEGF/VEGFR2 signaling can 
induce EC sprouting. We further examined the effect of pharmacological inhibitors on iPSC-
EC sprouting behavior in culture with either Growth Medium containing multiple growth 
factors including VEGF and FGF-2, or Starvation Medium containing VEGF alone (Fig. 
6B). Results demonstrated that sprouting in Starvation Medium with VEGF alone was 
inhibited in the presence of anti-angiogenic agents: receptor tyrosine kinase inhibitors 
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(SU1498, Sunitinib), a MEK inhibitor (PD0325901), a non-specific protein kinase inhibitor 
(Staurosporine), and a histone deacetylase inhibitor (Trichostatin-A) (Fig. 6B). Interestingly, 
sprouting behavior in the presence of Growth Medium was unaffected by treatment with 
SU1498 (Fig. 6B), a VEGFR2 inhibitor, and the longest continuous skeleton (defined as the 
longest branched skeleton for each condition) was significantly higher with SU1498 
treatment versus the VEGF-only condition without inhibition (Fig. 6D). These results 
suggest that VEGF/VEGFR2 signaling can induce iPSC-EC sprouting, and the influence of 
VEGF/VEGFR2 is dependent on the characteristics of the cell culture medium.
We hypothesized that the mechanism for VEGF-induced sprouting involved increased 
migration of iPSC-ECs, which is consistent with the role of VEGF for inducing endothelial 
cell chemotaxis[56, 57]. VEGF promoted iPSC-EC migration in a dose-dependent fashion 
(Fig. 8D), and treatment with a specific VEGFR2 inhibitor, SU1498, abolished iPSC-EC 
migration (Fig. 8E), suggesting that VEGF induced iPSC-EC migration through VEGFR2. 
Treatment with a FGFR/VEGFR2 inhibitor (SU5402) inhibited iPSC-EC migration (Fig. 
8B) and invasion (Suppl. Fig. 2B), further demonstrating that single-cell migration and 
invasion of iPSC-ECs was dependent on VEGF/VEGFR2 signaling. Taken together, our 
results suggest that VEGF/VEGFR2 was sufficient but not necessary to promote iPSC-EC 
sprouting, and VEGF/VEGFR2 signaling can promote single-cell migration whereas FGF2/
FGFR signaling may promote sprouting independently of VEGF.
Discussion
Current in vitro models of blood vessel function typically use primary human ECs that are 
derived from patients and expanded in vitro[58]. However, primary ECs exhibit tissue-
specific heterogeneity[11, 59] and present challenges for robust design of in vitro 
angiogenesis assays, including drug screening assays. Human pluripotent stem cells provide 
unique advantages for deriving tissue-specific cell types, and numerous protocols exist to 
differentiate stem cells into ECs[23–28]. iPSCs are a promising source of stem cells that can 
be readily differentiated to ECs and exhibit a diversity of vascular functions[60]. Here we 
used iPSCs-ECs, which exhibited a phenotype consistent with primary ECs (Figs. 1–2; 
Suppl. Fig. 1), exhibited thrombin-dependent barrier function (Fig. 2B), and responded to 
inflammatory stimulus (Fig. 2 C–F). Thus, iPSC-ECs provide a robust model system that is 
consistent with the phenotype and barrier function of primary ECs.
Angiogenesis is a complex process that involves a cascade of signaling molecules and 
regulatory events[61]. Here we found that iPSC-ECs responded to pro-angiogenic growth 
factors (e.g. VEGF; Fig. 1E–F, 7A, 8D), assembled into tubule networks in 2D (Fig. 3A–D) 
and 3D matrices (Fig. 3F), and formed perfusable tubule networks in 3D culture (Fig. 5, 
Suppl. Movie 1). iPSC-ECs aligned with flow in 2D (Fig. 4A–B) and elongated towards the 
axis of flow in 3D (Fig. 4C–F), consistent with a role of shear stress in inducing EC 
cytoskeletal arrangement[48]. The stem cell derived ECs exhibited sprouting in 3D spheroid 
culture that was dependent on VEGF concentration (Fig. 7A) and FGFR/VEGFR2 signaling 
(Fig. 6B, 7B), consistent with the role of VEGF/VEGFR2 and FGF2/FGFR signaling for 
promoting endothelial cell sprouting[62]. We also observed complete inhibition of iPSC-EC 
sprouting in the presence of PD0325901 (Fig. 6B), a MAPK/ERK inhibitor, which is 
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consistent with the role of ERK1/2 to promote sprouting angiogenesis[63]. Together these 
results demonstrate that iPSC-ECs exhibit functional properties consistent with those 
reported for primary ECs and associated with those needed for robust screening assays.
We further investigated the utility of iPSC-ECs as a well-defined cell type to screen for the 
influence of pharmacological agents using a quantitative angiogenesis assay. Known 
pharmacological protein kinase inhibitors that have been previously investigated as 
therapeutic antiangiogenic agents disrupted iPSC-EC sprouting in our experiments, 
including inhibitors of MEK (PD0325901 [63]), protein kinases (Staurosporine[64]), histone 
deacetylases (Trichostatin A[65]), and receptor tyrosine kinases (Sunitinib[66]). SU1498 
(tyrphostin)[31] and Sunitinib blocked sprouting for iPSC-ECs in serum-containing medium 
with only VEGF (Fig. 6E), which confirms a role of VEGF/VEGFR2 for inducing 
sprouting[50, 67]. Interestingly, VEGFR2 inhibition with SU1498 did not affect iPSC-EC 
sprouting in Growth Medium containing multiple growth factors including VEGF and 
FGF-2 (Fig. 6B), and the longest continuous skeleton was increased relative to VEGF-
containing Starvation Medium (Fig. 6D), suggesting EC sprout length was enhanced by 
VEGFR2 inhibition. However, iPSC-EC sprouting was completely abolished by the 
combined VEGFR2/FGFR inhibitor SU5402 [68] (Fig. 6B) suggesting a role for FGF2/
FGFR signaling in promoting maximal sprout formation that is consistent with previous 
studies examining bovine luteal endothelial cell tube formation[62]. These results are also 
consistent with previously reported roles for FGF2/FGFR signaling in promoting EC 
sprouting[50, 62, 69] and increasing vascular integrity independently of VEGF/VEGFR2 
signaling[70]. We posit that VEGF signaling may provide a “switch” from a sprouting 
phenotype to a single cell migration phenotype that is relevant to therapeutic strategies and 
may provide an explanation for the limited efficacy of anti-angiogenesis therapies targeting 
VEGF alone. Our results suggest that FGF2/FGFR signaling may be a useful target for 
increasing the efficacy of anti-angiogenic therapies that are currently based on VEGF/
VEGFR2 inhibition.
Our results also provide evidence that enhancement of sprouting angiogenesis by VEGFR2 
inhibition is due to a role for VEGF signaling in modulating EC phenotype (Fig. 6D–E, Fig. 
7A–B). While cumulative sprouting length was unaffected by VEGFR2 inhibition in Growth 
Medium, sprouting was abolished by VEGFR2 inhibition in VEGF-containing medium as 
well as by combined FGFR/VEGFR2 inhibition in both Growth and VEGF-containing 
medium (Fig. 6B). However, VEGF/VEGFR2 inhibition by SU1498 in Growth Medium 
increased the longest continuous skeleton relative to VEGF-containing Starvation Medium 
(Fig. 6D). Since the “cumulative sprout length” measurement here represents both single-
cell migration and sprouting, our data suggest that a larger value of the “longest continuous 
skeleton” corresponded to increased sprouting and decreased single-cell migration in 
Growth Medium containing SU1498. This conclusion is supported by evidence showing that 
VEGFR2 inhibition abolished VEGF-mediated single-cell migration (Fig. 8E). 
Angiogenesis requires a complex interplay of numerous growth factors that are tightly 
regulated[61]. Thus, it is reasonable to expect that synergy between multiple pro-angiogenic 
growth factors can modulate the process of sprouting angiogenesis, and VEGF inhibition 
may enhance sprouting angiogenesis by amplifying the effects of other pro-angiogenic 
growth factors, including FGF2 [61]. Based on the combined results, we hypothesize that 
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VEGF inhibition decreases EC single cell migration and may promote sprouting, which 
could have important implications related to the confounding results of anti-VEGF therapy 
to reduce tumor growth[71].
Our assessment of sprouting behavior in iPSC-ECs showed inhibition with specific anti-
angiogenic agents, and the inhibition was dependent on the characteristics of the cell culture 
medium. SU5402 and nocodazole exhibited IC50 values of 4 and 8nM respectively for 
inhibiting iPSC-EC proliferation (Suppl. Fig. 3B–C), and exhibited IC50 values of 730nM 
and 100nM respectively for inhibiting iPSC-EC sprouting (Fig. 7 B,C). These results 
illustrate that nocodazole and SU5402 potencies were 13-fold and 200-fold higher, 
respectively, for inhibiting proliferation versus inhibiting sprouting. Proliferation and 
sprouting inhibition with nocodazole agrees with the previously measured potency of 
nocodazole for inhibiting cell proliferation and tubule network formation[54]. Further, 
SU5402 inhibition of iPSC-EC proliferation is in agreement with previously measured 
potency of SU5402 for inhibiting primary EC proliferation[68]. The observed inhibition of 
VEGF-dependent iPSC-EC sprouting at 1 µM SU5402 is consistent with previously 
measured SU5402 inhibition of VEGF- and FGF2-dependent tubule network formation for 
primary ECs[62, 72]. These studies highlight the importance of context for drug screening 
applications, as growth factor signaling[61, 73, 74] and the cellular cytoskeleton[54] exhibit 
different effects on EC function (i.e. proliferation, migration, tubule network formation, and 
sprouting) during angiogenesis.
Conclusions
Stem cell technology enables the development of tissue models that use differentiated iPSCs 
to provide standardized quantitative readouts for tissue engineering, drug development, 
toxicity screening, and disease modeling. Here we demonstrate the utility of a defined iPSC-
EC source for modeling vascular tissue formation within 3D microenvironments, and for 
profiling the influences of specific pharmacologic agents. Our results demonstrate the 
potential for a well-defined source of iPSC-ECs to investigate vascular biology within 
engineering contexts, including single cell and spheroid encapsulation within natural 
matrices and culture within microfluidics devices and bioreactor systems. The iPSC-ECs 
expressed EC markers consistent with primary ECs and exhibited functional EC properties, 
such as the uptake of LDL, formation of a thrombin-dependent barrier, cytoskeletal 
rearrangement in the presence of flow, and perfusable tubule network formation in 3D 
contexts. Further, iPSC-ECs responded to wound healing stimuli by upregulating expressing 
of ICAM and MCAM, and exhibited VEGF-dependent proliferation and sprouting. We 
developed a novel sprouting assay with iPSC-ECs that quantitatively assessed growth factor 
stimulation and pharmacological inhibition. The sprouting model provided new insight into 
synergistic roles for VEGF and FGF signaling during angiogenesis wherein inhibition of 
VEGFR2 signaling enhances maximal sprout formation. Thus, our results demonstrated that 
VEGF/VEGFR2 signaling is a sufficient but not necessary condition to induce iPSC-EC 
sprouting. Hence, iPSC-ECs provide a robust, stable, and reproducible model system for in 
vitro angiogenesis that enables basic biological research and molecular pharmacology 
studies with the potential to generate donor specific disease models.
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MATERIALS AND METHODS
Cell culture
iPSC-ECs used for all experiments were obtained from Cellular Dynamics International, Inc. 
(CDI, Madison, WI) and cultured according to the manufacturer’s protocols. Briefly, iPSC-
ECs were plated onto Fibronectin (3 µg/cm2, Invitrogen) coated tissue culture plates at 
10,000–15,000 cells/cm2 and passaged every three to four days with TrypLE (Invitrogen). 
iPSC-ECs were cultured using VascuLife VEGF Medium (Lifeline Cell Technologies, 
Frederick, MD) supplemented with the complete growth factors per the kits. Here, only 10 
mL of the glutamine solution was added per 500 mL media and 50 mL of the CDI provided 
supplement replaced the VascuLife FBS component. Hereafter, this medium is referred to as 
“Growth Medium”, and cells in all contexts were cultured at 37°C, 5% CO2, 5% O2
Flow cytometry
iPSC-ECs were harvested with TrypLE and stained with either isotype control or antigen-
specific antibodies. Cell-surface antigen expression was analyzed using fluorescently 
conjugated antigen-specific antibodies against VEGFR2/KDR (R&D Systems, clone 
89106), CD31 (BD Biosciences, clone WM59), CD105 (eBiosciences, clone SN6) and 
CD144 (eBiosciences, clone 16B1). The cells were also tested for contaminating iPSCs 
using an antibody against TRA-1-81 to confirm a negative result (Stemgent, San Diego, 
CA). Internal antigen expression was analyzed using methanol fixed cells permeabilized 
with PBS + 0.1% saponin/BSA. Unconjugated polyclonal rabbit anti-human von Willebrand 
Factor (Dako, Carpinteria, CA) was detected with an Alexa Fluor 488 goat anti-rabbit 
secondary antibody (Molecular Probes, Eugene, OR). Cells were analyzed on an Accuri 
flow cytometer (BD Biosciences) using propidium iodide, when appropriate, to exclude 
dead cells. iPSC-ECs exhibited a purity of ≥ 90% as measured by high coexpression of 
CD31 with CD105 or CD144 by flow cytometry.
Tube formation on Matrigel
Matrigel (0.2 mL; BD Biosciences) was added to each well of a 24-well tissue-culture plate 
and allowed to solidify at 37°C for at least 30 minutes. Following gelation, 0.2 mL of a cell 
suspension containing 1 × 105 iPSC ECs in Growth Medium was placed on top of the 
Matrigel. The cultures were incubated at 37°C, 5% CO2, and observed at 24, 48, and 72 
hours for observation of cellular formation into capillary-like structures. Ulex staining: 
Matrigel tubes were stained with the lectin Ulex europaeus (Sigma) after 24 hours to 
confirm the presence of human endothelial cells in the vessel-like formations. Briefly, 
Growth Medium was removed from the Matrigel layer and tubes were incubated with 10 
µg/ml Ulex for 30 minutes at room temperature followed by imaging.
Immunostaining
Cells were stained as below, washed, and nuclei were counterstained using Hoechst 33342 
(Invitrogen) for imaging. AcLDL: Analysis for the acetylated LDL receptor mediated uptake 
of AcLDL was performed overnight at 37°C, 5% CO2 in iPSC EC growth medium 
containing 2.5 µg/ml Alexa Fluor 594 AcLDL (Molecular Probes) followed by imaging. 
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Prior to immunostaining, proprietary CDI supplement contained in the medium was reduced 
to ≤5%. vWF: iPSC-ECs were fixed with methanol, blocked for 30 min. with PBS 
containing 10% FBS + 0.1% NaN3, and stained with 0.5 µg/ml vWF for 1 hour. Secondary 
antibody was added at a 1:500 dilution for 30 min. Antibodies were diluted in PBS 
containing 2% FBS + 0.1% NaN3 and were the same as those used in flow cytometry for the 
detection of the von Willebrand factor/factor VIII complex (Dako, Carpinteria, CA). All 
staining was carried out at room temperature. Z0-1: The tight junction protein ZO-1 analysis 
on the iPSC-ECs was carried out using an Alexa Fluor 488 ZO-1 antibody (Molecular 
Probes). Cells were fixed with 4% paraformaldehyde, permeabilized with PBS + 0.1% 
saponin/BSA, and stained overnight with 2 µg/ml Z0-1 at 4°C prior to imaging.
Barrier Function
To measure barrier function and endothelium permeability of iPSC-ECs, an impedance-
based platform was employed (xCelligence, ACEA system). In brief, one E-plate Cardio 96 
plate was pre-coated with fibronectin (15 µg/cm2, Invitrogen) for 1 hour at room 
temperature. Fibronectin solution was then aspirated from wells and replaced with 0.15 mL 
per well of Growth Medium. The plate was incubated for 5 minutes, after which a 
background measurement was recorded. Wells were aspirated, and iPSC-ECs were seeded in 
Growth Medium at 64,000 cells/mL in a final volume of 0.15 mL/well (~30,000 cells/cm2). 
Cells were incubated for 30 minutes at room temperature and transferred to 37°C, 5% CO2 
for 2 days. At day 2 post-plating, 0.1 mL of spent medium was exchanged with 0.13 mL of 
fresh 37°C Growth Medium (leaving a total of 0.18 mL in each well), and plate was 
incubated for at least 1 hour at to 37°C, 5% CO2. A background measurement was recorded 
before the start of the experiment. Barrier function was disrupted by the addition of 20 µL of 
a 10× solution of thrombin (Sigma) to each well to achieve a final concentration of 0 
(control), 0.5, 1, 1.5, or 5 U/ml. The cellular response to thrombin was then monitored for 
2.5 hours to observe recovery of the barrier function.
Proliferation Assay
The proliferation of iPSC-ECs was assessed using the Cell Titer-Glo Luminescent Cell 
Viability Assay (Promega). Cells were plated to a 96-well tissue culture plate (Corning) pre-
coated with fibronectin (3 µg/cm2, Invitrogen) at 5,000 cells/cm2 in a final volume of 100 
µL/well. The plate was incubated at 37°C, 5% CO2, 5% O2 for 24 hours at which time the 
medium was exchanged with 100 µL/well of fresh Growth Medium or Starvation Medium, 
containing VascuLife Basal Medium with 4 mM L-glutamine and 0.1 vol.% iPSC-EC 
supplement (CDI). Cells in Growth Medium were assayed at 72, 96, and 120 hours (days 3, 
4, and 5) post-plating, with an additional fresh medium exchange at 96 hours post-plating. 
At 48 hours post-plating, cells in Starvation Medium were fed fresh Starvation Medium 
containing a seven-point titration (2-fold dilution series) of VEGF with a maximal highest 
concentration of 80 ng/ml). In addition, a dilution series of the VEGFR2-inhibitor 
(Tyrphostin SU1498; Sigma) was also prepared with the highest concentration of 40 µM in 
the presence or absence of 5 ng/ml of VEGF. 48 hours after treatment, the cells were fed 
with fresh Starvation Medium containing the same compound titrations and assayed the 
following day (totaling day 5 post-plating). The amount of cellular ATP was quantified 
using Cell Titer-Glo per the manufacturer's instructions. Luminescence readings were taken 
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using the Tecan GENios Pro Microplate Reader (1 second integration time/sample). 
Proliferation fold induction was calculated relative to the values obtained with cells 
maintained in starvation medium. Standard deviation was calculated from triplicate wells.
2D Shear Stress Experiments
To investigate the response to shear stress, endothelial monolayers were cultured under 
static and flow conditions. For dynamic cultures, monolayers were subjected to 
unidirectional flow at 20 dyne/cm2 for 72 hours using a software controlled perfusion 
system (Ibidi pump system, red perfusion set: 15cm ID 1.6mm, Ibidi) according to the 
manufacturer guidelines. Confluent endothelial monolayers were generated by seeding 
single cells on fibronectin coated slides (µ-slide I0.6, IbiTreat) at 1×105 cells/cm2 and 
subsequently cultured under static conditions overnight in growth medium at 37°C and 5% 
CO2. Prior to flow initiation, culture medium was exchanged for fresh growth medium 
supplemented with 10% FBS. At the end of the experiment, monolayers were fixed (4% 
paraformaldehyde) and stained for cell-cell junctions and nuclei with anti-VE-Cadherin and 
DAPI respectively.
Microfluidic Experiments
The procedure for forming perfusable microvascular networks in a multi-culture 
microfluidic system is described in detail elsewhere[75]. Briefly, a PDMS device containing 
three parallel gel regions – each separated by a medium channel – was permanently bonded 
to a glass coverslip. The middle gel region was filled with a 2.5 mg/ml fibrin gel containing 
iPSC-ECs at 3.5 million cells/ml. The two side gel regions were filled with fibrin gel 
containing normal human lung fibroblasts (NHLFs; Lonza, MD, USA) with the same gel 
concentration and cell density as for iPSC-ECs. The devices were incubated at room 
temperature for 10 min to allow the gel to polymerize before adding warm growth medium 
supplemented with 250 nM sphingosene-1-phosphate (S1P; Sigma, MO, USA) to the 
medium channels. Fresh medium was replenished every two days. After 4 days, the devices 
were fixed with 4% paraformaldehyde and stained for actin and nuclei with phalloidin and 
DAPI respectively. To demonstrate flow through the live and fixed networks, we perfused 
the system with medium containing 4 µm fluorescent microspheres (Life Technologies; NY, 
USA) by imposing a hydrostatic pressure drop across the vascularized gel region. This was 
readily accomplished by filling the medium channel on one side of the vascularized gel 
region 1–2 mm higher than the other side.
Alignment and Network Formation Assay
iPSC-ECs (passage 3) were harvested with TrypLE and resuspended in 4°C Matrigel (BD 
Biosciences) at 5 million cells/ml. 200 µL of cell-containing Matrigel solution were placed 
onto circular uncoated 1 cm diameter scaffolds (Zyoxel, LC15) held down by retaining rings 
against LiverChip™ filters (Zyoxel, LC17) within a LiverChip™ perfusion plate (Zyoxel, 
LC-CP and LC-PP) and allowed to form hydrogels (8 hydrogels of 200 µL volume each) at 
room temperature for 10 minutes before adding 1.7 mL of medium, which was replenished 
every other day. The perfusion plate was assembled and operated as illustrated in Fig. 3E 
according to the manufacturer guidelines. The medium flow was set to 0.3 µL/s downward 
into the hydrogel throughout the entire timespan of the experiment. At the indicated times, 
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two scaffolds were sacrificially removed from the perfusion plate and incubated in media in 
the presence of 1 µg/mL calcein AM (Life Technologies) for 40 minutes at 37°C and imaged 
immediately after using an inverted epifluorescence microscope.
Sprouting Assay
Sprouting behavior of iPSC-ECs was assessed by culturing the cells in a spheroid as shown 
(Fig. 6A). iPSC-ECs at between Passage 2–6 were seeded into non-adherent round bottom 
96 well plates (Corning) at 500 cells/well in 20 vol.% methylcellulose (Sigma; 600 mg/L in 
phosphate buffered saline) and 80 vol.% Starvation Medium (with 10 vol.% CDI 
supplement). After 24 hours, half of the medium was replaced with 40 vol.% Matrigel in 
PBS, making a gel containing 20 vol.% Matrigel after 4 hours at 37°C, 5% CO2, and 95% 
relative humidity. Subsequently, the culture conditions described in Figs. 6–7 were added at 
100 µL per well. For inhibition studies, either Starvation Medium with 20 ng/mL VEGF or 
Growth Medium was added containing 0.1 vol.% of inhibitor stock solutions. For VEGF 
titration, a 2-fold serial dilution was prepared in Starvation Medium. Finally, for nocodazole 
and SU5402 titration, a 2-fold serial dilution was prepared in Starvation Medium with 20 
ng/L VEGF. Cultures were maintained for 6 days, with medium changes every other day. 
On the final day, cells were stained with 2 µg/mL Calcein-AM and 4 µg/mL Ethidium 
Homodimer-1, and cells were imaged using epifluoresence. Images were processed using 
ImageJ. Specifically, images were uniformly thresholded and auto-contrasted using the Otsu 
method, and the Skeleton plugin was utilized to skeletonize fluorescent images and analyze 
the total length of the skeletonized network (in pixels). For the analysis in Fig. 6D, the 
“longest continuous skeleton” measurement was defined as the skeleton with the largest 
cumulative length of branches in a given skeleton identified via the skeleton analysis. 
Conditions were performed in sextuplicate and compared via two-tailed Student’s t-test at p-
value<0.05. For statistical analysis of growth factor and inhibitor concentration screening, 
sigmoidal regression analysis was performed in Prism (GraphPad), and IC50 values and 
EC50 values were calculated for each condition. Data is presented as the mean value +/− one 
standard deviation.
Migration Assay
To measure migration of iPSC-ECs, an impedance based system was employed 
(xCelligence, ACEA system). In brief, the underside of the upper chamber of CIM-plates 
was pre-coated with fibronectin (15 µg/cm2, Invitrogen) for 1 hour at room temperature. 
Medium conditions were prepared in Starvation Medium with VEGF (R&D Systems) at the 
concentrations in Fig. 7D or 20 ng/mL VEGF with the inhibitor concentrations in Fig. 8B–
D. Medium was added to the bottom chamber of CIM plates, and the bottom and top 
chambers were assembled prior to experimentation. iPSC-ECs between Passage 2–4 were 
seeded at 10000 cells well−1 in a total volume of 100 µL in Starvation Medium with the 
inhibitor concentrations listed in Fig. 7 at 0.1 vol.% DMSO. Plates were incubated at 37°C, 
5% CO2, and 95% relative humidity for 24 hours with data collected every 15 minutes. After 
24 hours, the final cell indices were correlated to the experimental conditions, which were 
performed in triplicate and compared via Student’s t-test at p-value<0.05.
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Figure 1. iPSC-ECs stably express common endothelial cell markers and proliferate in response 
to VEGF/VEGFR2 signaling
(A) FACs analysis for PECAM / Endoglin co-expression.
(B) FACs analysis illustrating PECAM / VE-cadherin co-expression.
(C) iPSC-ECs maintain purity for at least 6 passages based on FACs analysis of CD31/
CD105 co-expression. Average of 3 separate lots, 3 thaws each (9 samples total). Error bars 
= S.D.
(D) FAC analysis for iPSC-EC expression of VEGFR-2 (KDR/Flk1). iPSC proliferation in 
response to (E) VEGF treatment (in Starvation Medium), and (F) when treated with the 
VEGFR-2 inhibitor SU1498 in Starvation Medium with 0 (white diamonds) or 5 ng/mL 
VEGF (black diamonds).
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Figure 2. iPSC-EC expression and function
(A) iPSC-ECs express ZO-1 tight junction protein at cell borders.
(B) iPSCs exhibit thrombin-dependent barrier function. Traces in red represent control 
conditions without thrombin. Blue, green, and black traces represent cell index over time in 
the presence of thrombin at 0.5 U/mL, 1.5 U/mL, or 5 U/mL respectively.
(C–F) Upregulation of cell adhesion molecules (C–D) CD54 (ICAM1) and (E–F) CD146 
(MCAM) for iPSC-ECs in response to treatment with 25 µg/mL TNF-α for 24 hours. 
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ICAM1 expression (C) before and (D) after TNF-α treatment. MCAM expression (E) before 
and (F) after TNF-α treatment.
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Figure 3. Tube forming assays for endothelial cells in 2D and 3D environments
(A–B) 2D tube-forming assay on Matrigel (coated TCP plate) for (A) iPSC-ECs and (B) 
HUVECs.
(C–D) 3D tube-forming assay for iPSC-ECs in a thick layer of Matrigel; (C) Brightfield 
microscopy and (D) UEA-1 fluorescence imaging. UEA-1 is highly specific for EC lectin 
(fucose) [Jackson, JCS 1990].
(E) Schematic of 3D iPSC-EC encapsulation in Matrigel within a custom bioreactor to 
provide flow in the direction of the dashed arrows.
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(F) Maximum intensity projection of iPSC-ECs encapsulated in Matrigel (3D) and stained 
with Calcein-AM after 2 days of culture in the bioreactor from (E).
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Figure 4. iPSC-EC organization when subjected to flow
(A–B) iPSC-ECs cultured in a microfluidics channel and subjected to lateral flow (shear 
stress = 20 dyn/cm2) to verify the capacity for alignment. Cells were randomly oriented 
without flow (A) but adopted elongated morphologies in the direction of an applied (left to 
right) shear stress (B).
(C–D) Representative maximum intensity projection of iPSC-ECs encapsulated in Matrigel 
and cultured in a bioreactor for 4 days (as shown in Fig. 3E). Cells exhibited a rounded 
morphology in the absence of flow, but adopted an extended morphology towards the 
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central axis of flow along the periphery of each channel. Channels were formed from 340µm 
pores (outlined in dotted white line) wherein flow was provided in the z-direction (into the 
frame of the micrographs. Z-stack = 300µm, z-slice thickness = 3µm
(E–F) Representative maximum intensity projections of HUVECs (E) and iPSC-ECs (F) 
cultured in bioreactor (schematic Fig. 3E). Cells in the presence of flow exhibited an 
elongated morphology towards the central axis of flow (denoted by white arrowheads). Z-
stack = 300µm, z-slice thickness = 3µm
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Figure 5. iPSC-ECs form perfusable capillaries in a microfluidics device
iPSC-ECs encapsulated in fibrin within a central microfluidics channel with adjacent 
channels containing encapsulated fibroblasts.
(A) After 4 days in culture with S1P-containing medium, iPSC-ECs encapsulated in central 
chamber were stained with FITC-Phalloidin and DAPI and were imaged using confocal 
laser scanning microscopy (A.i–ii). Scale bar: 100 µm (A.iii) Confocal image of iPSC-ECs 
stained with FITC-Phalloidin and DAPI, demonstrating that tubules contained a hollow 
lumen. Scale bar: 10µm
(B) 4µm fluorescent microspheres were added to the channel and constrained to endothelial 
cell-lined tubes, demonstrating that iPSC-EC tubules were perfusable over time (Time scale 
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= 119ms). Microspheres appear as a streak of ~15µm indicating movement in a given shutter 
exposure. Scale bar: 10 µm
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Figure 6. VEGF/VEGFR2 signaling is necessary but not sufficient to induce iPSC-EC sprouting
(A) Schematic of cell spheroid formation in round-bottom low adhesion plates using 
Matrigel as a substrate to enable iPSC-EC sprouting. Analysis was performed after 7 total 
days in culture using Calcein-AM.
(B) Quantification of total sprout length of iPSC-ECs cultured in a VEGF-only solution or 
Full Supplement (containing VEGF, FGF-2, IGF-1, and EGF) along with a library of 
pharmacological inhibitors. The control condition with 10 vol.% serum and no growth 
factors is shown by a dashed line, and +/1 standard deviation is shown as a gray bar. 
Statistical significance compared to the control is denoted for p-value < 0.05 (*).
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(C) Fluorescent micrographs demonstrating sprouting after 6 full days in culture with 
Matrigel. Cells were stained with Calcein-AM and Ethidium Homodimer-1. Scale bar 
represents 200 µm. Image series demonstrates sprouting in the presence of growth medium 
(C.i) with SU5402 (ii), nocodazole (iii.), or SU1498 (iv.).
(D) Quantification of mean length of longest branched sprout in a subset of conditions in 
(B), showing increased longest continuous skeleton in SU1498-containing medium with 
Growth Medium. Statistical significance compared to the conditions in brackets is denoted 
for p-value < 0.05 (*).
(E) Total sprout length as a function of VEGF in 2 and 10 vol.% serum with no inhibitor, 
SU1498, or Sunitinib. Statistical significance compared to no inhibitor conditions denoted 
for p-value < 0.05 (*)
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Figure 7. iPSC-EC sprouting depends on both VEGF signaling and microtubule polymerization
(A) iPSC-EC total sprout length as a function of VEGF concentration. Sigmoidal regression 
analysis was used to calculate an EC50 value for VEGF.
(B,C) Analysis of sprouting inhibition with SU5402 (B) and nocodazole (C) at a range of 
concentrations. Sigmoidal regression analysis was used to calculate an IC50 value for each 
inhibitor.
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Figure 8. iPSC-EC migration is dependent on VEGF/VEGFR2 signaling and microtubule 
organization
(A,B) End-point analysis of iPSC-EC migration quantified using real-time impedance 
measurements in different concentrations of SU5402 (A) or nocodazole (B) in medium 
containing 10 vol.% serum with 20ng/mL VEGF in the bottom chamber and 10 vol.% serum 
and no VEGF in the top chamber. Statistical significance compared to the control without 
inhibitor is denoted is denoted for p-value < 0.05 (*).
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(C) End-point analysis of iPSC-EC migration in different concentrations of VEGF, added 
only to the bottom chamber. Sigmoidal regression analysis was used to calculate an EC50 
value for VEGF
(D) End-point analysis of iPSC-EC migration in the presence of the VEGF receptor tyrosine 
kinase inhibitor SU1498. Statistical significance compared to the no inhibitor control is 
denoted for p-value < 0.05 (*).
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